The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC, a biopharmaceutical company specializing in innovative therapies for acute and life-threatening conditions, are excited to announce Melinta’s membership in NHIA’s Future of Infusion Advisory Council (FIAC). This strategic advisory group consists of leading manufacturers and service providers committed to advancing the home and alternate-site infusion industry. FIAC collaborates closely with NHIA staff and its Board of Directors to address key issues, challenges, and growth opportunities within this dynamic segment of healthcare.
For Melinta, joining FIAC is a significant step toward fostering collaboration with industry leaders and organizations that support patients requiring infusion therapies. This partnership aims to improve continuity of care for patients transitioning from hospital settings to home-based or alternate infusion sites, ensuring seamless, effective treatment delivery.
Enhancing Patient Care Through Collaboration
“We’re thrilled to join FIAC and work closely with healthcare professionals to enhance both the immediate and long-term patient experience,” stated John Harlow, Chief Commercial Officer at Melinta. “Through our partnership with NHIA, we’ve gained deeper insights into the home infusion marketplace and the evolving needs of our customers. By addressing the challenges and opportunities in outpatient infusion, we can collectively make a meaningful difference in patient care today and in the future.”
Melinta is dedicated to delivering innovative therapies to address unmet medical needs, focusing on acute and life-threatening illnesses. By engaging with healthcare providers and leveraging collaboration, the company strives to ensure that patients in need of its therapies can access them promptly and effectively.
A Shared Vision for Advancing the Infusion Industry
The NHIA views Melinta’s participation in FIAC as a natural extension of their longstanding partnership. According to Connie Sullivan, NHIA President and CEO, “We are excited to deepen our collaboration with Melinta through their involvement in FIAC. This partnership allows us to work with industry leaders to enhance the ways we serve the infusion community, ultimately enabling more patients to lead healthier, independent lives.”
Through FIAC, Melinta will contribute to shaping the future of home and alternate-site infusion services. The advisory council’s collective expertise ensures that innovative solutions are developed to address emerging challenges in the field, such as evolving regulatory requirements, technological advancements, and patient-centered care models.
Supporting a Growing Healthcare Segment
Home and alternate-site infusion therapy is a rapidly growing segment of the healthcare industry. It offers a cost-effective and convenient option for patients who require intravenous medications, allowing them to receive high-quality care in the comfort of their homes or other non-hospital settings. This model not only improves patient satisfaction but also helps alleviate pressure on hospital resources.
Melinta’s membership in FIAC reinforces its commitment to supporting this evolving landscape. By collaborating with NHIA and other stakeholders, the company aims to ensure that patients receive the highest standard of care as they transition between care settings.
